Advertisement
Screener

BeyondSpring Inc. (BYSI) Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest

1.4 / 5 stars · 10/37 Roast Me

BeyondSpring Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest

BeyondSpring Inc. (BYSI) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$841.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2026-08-14

  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$841.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$132.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$136.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2025-09-30 was $41.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2025 was -$242.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2024 was -$388.00K.
  • BeyondSpring Inc. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2023 was -$922.00K.
Period endIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month
2026-06-30-$841.00K
10-Q · filed 2026-08-14
-$973.00K
10-Q · filed 2026-08-14
-$1.11M
derived: sum of 3 quarters · filed 2026-08-14
-$1.07M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$132.00K
10-Q · filed 2026-05-13
-$268.00K
derived: sum of 2 quarters · filed 2026-05-13
-$227.00K
derived: sum of 3 quarters · filed 2026-05-13
-$299.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$136.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$95.00K
derived: sum of 2 quarters · filed 2026-03-25
-$167.00K
derived: sum of 3 quarters · filed 2026-08-14
-$242.00K
10-K · filed 2026-03-25
2025-09-30$41.00K
10-Q · filed 2025-11-12
-$31.00K
derived: sum of 2 quarters · filed 2026-08-14
-$106.00K
10-Q · filed 2025-11-12
-$296.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$72.00K
10-Q · filed 2026-08-14
-$147.00K
10-Q · filed 2026-08-14
-$337.00K
derived: sum of 3 quarters · filed 2026-08-14
-$420.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$75.00K
10-Q · filed 2026-05-13
-$265.00K
derived: sum of 2 quarters · filed 2026-05-13
-$348.00K
derived: sum of 3 quarters · filed 2026-05-13
-$406.00K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$190.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25
-$273.00K
derived: sum of 2 quarters · filed 2026-03-25
-$331.00K
derived: sum of 3 quarters · filed 2026-03-25
-$388.00K
10-K · filed 2026-03-25
2024-09-30-$83.00K
10-Q · filed 2025-11-12
-$141.00K
derived: sum of 2 quarters · filed 2025-11-12
-$198.00K
10-Q · filed 2025-11-12
2024-06-30-$58.00K
10-Q · filed 2025-08-13
-$115.00K
10-Q · filed 2025-08-13
2024-03-31-$57.00K
10-Q · filed 2025-05-12
2023-12-31-$922.00K
10-K · filed 2025-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Context Therapeutics Inc. (CNTX)United States$0.034B-1.10
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30